Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation

Transplant International

Volumn 18, Issue 2, 2005, Pages 169-176

  Klingenberg, Roland ^a   Koch, Achim ^a   Gleissner, Christian ^a   Schnabel, Philipp A ^a   Haass, Markus ^a   Remppis, Andrew ^a   Katus, Hugo A ^a   Dengler, Thomas J ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

B type natriuretic peptide; Cross sectional observational study; Determinants; Heart transplantation; Late post transplant phase

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIOPSY; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DONOR; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VASCULAR DISEASE; BLOOD; CROSS-SECTIONAL STUDY; GRAFT REJECTION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; VENTRICULAR FUNCTION, LEFT;

EID: 20444502193     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.00010.x     Document Type: Article

References (38)

1. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988.
2. Luchner A, Hengstenberg C, Lowel H, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002; 39: 99.
3. Lubien A, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595.
4. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587.
5. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386.
6. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392.
7. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: a randomised comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138: 1126.
8. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126.
9. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246.
10. McCollough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2004; 4: S13.
11. Atoniu A, Burch M, Singer D, Littleton P, Carter N. Cardiac transplantation affects ventricular expression of brain natriuretic peptide. Cardiovasc Res 1993; 27: 188.
12. El Gamel A, Yonan NA, Keevil B, et al. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Ann Thorac Surg 1997; 63: 1095.
13. Park MH, Scott RL, Uber PA, Harris BC, Chambers R, Mehra MR. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol 2002; 90: 1326.
14. Maisel A. B-type natriuretic peptide levels: a potential novel 'white count' for congestive heart failure. J Card Fail 2001; 7: 183.
15. Akiba T, Tachibana K, Togashi K, Hiroe M, Marumo F. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol 1995; 44: S61.
16. Armstrong AT, Binkley PF, Baker PB, Myerowitz PD, Leier CV. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 1998; 32: 704.
17. Geny B, Charloux A, Lampert E, Lonsdorfer J, Haberey P, Piquard F. Enhanced brain natriuretic peptide response to peak exercise in heart transplant recipients. J Appl Physiol 1998; 85: 2270.
18. Sakata Y, Yamamoto K, Masuyama, T et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001; 19: 1905.
19. Yamani MH, Haji SA, Starling RC, et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 2002; 39: 970.
20. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999; 100: 287.
21. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
22. Gao S-Z, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12: 334.
23. Vogeser M, Jacob K. B-type natriuretic peptide (BNP) - validation of an immediate response assay. Clin Lab 2001; 47: 29.
24. Hosenpud JD, Bennett LE, Keck BM, Boncek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report - 2000. J Heart Lung Transplant 2000; 19: 909.
25. Troughton RW, Prior DL, Pereira JJ, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004; 43: 416.
26. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000; 167: 239.
27. Espiner EA, Richards AM, Yandle TG, Nicholls MG. Natriuretic hormones. Endocrinol Metab Clin North Am 1995; 24: 481.
28. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993; 291: 83.
29. Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004; 50: 1071.
30. Alehagen U, Lindstedt G, Eriksson H, Dahlstrom U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 2003; 49: 1337.
31. Ambrosi P, Oddoze C, Riberi A, et al. Aminoterminal pro-brain natriuretic peptide and ventricular filling pressures in heart transplant recipients. J Heart Lung Transplant 2003; 22: 822.
32. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci 2001; 101: 447.
33. Noubani A, Farookhi R, Gutkowska J. B-type natriuretic peptide receptor expression and activity are hormonally regulated in rat ovarian cells. Endocrinology 2000; 141: 551.
34. Jankowski M, Rachelska G, Donghao W, McCann SM, Gutkowska J. Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc Natl Acad Sci USA 2001; 98: 11765.
35. Karjalainen AH, Ruskoaho H, Vuolteenaho O, et al. Effects of estrogen replacement therapy on natriuretic peptide and blood pressure. Maturitas 2004; 47: 201.
36. Gleissner CA, Murat A, Schafer S, et al. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation 2004; 77: 710.
37. Park MH, Uber PA, Nasca PF, Scott RL, Mehra MR. Temporal alteration in B-type natriuretic peptide expression predicts allograft failure in heart transplantation [abstract]. J Heart Lung Transplant 2003; 22(S1): 157.
38. Geny B, Follenius M, Epailly E, et al. Transient reduction without normalization of brain natriuretic peptide early after heart transplantation. J Thorac Cardiovasc Surg 1998; 115: 473.